Summary. Ninety-two and 33 methicillin-resistant Staphylococcus aureus (MRSA) strains were isolated in Japan and China respectively. They were categorised as ofloxacin-susceptible (MIC < 12.5 mg/L), moderately (MIC 12.5-25 mg/L) or highly (MIC 2 50 mg/L) ofloxacinresistant. 4-Quinolone concentrations required to inhibit purified DNA gyrase from the moderately and highly quinolone-resistant MRSA were at least 20 times higher than those required to inhibit the equivalent enzyme from quinolone-susceptible strains. Reconstitution assays demonstrated that the 4-quinolone-resistant MRSA had a mutation in subunit A of DNA gyrase. A portion of the gyrA gene from amino acids codons 40-1 15 was sequenced. Four moderately resistant and seven highly resistant MRSA contained a Ser + Leu substitution at amino acid 84; one moderately and one highly resistant MRSA and one moderately resistant methicillin-susceptible S. aureus (MSSA) strain contained a Glu --+ Lys substitution at amino acid 88. Eight MRSA, including one quinolone-susceptible strain and one MSSA contained a silent mutation at amino acid 86. Uptake of ofloxacin in moderately resistant strains was almost the same in the presence or absence of carbonyl cyanide mchlorophenylhydrazone (CCCP), whereas in highly resistant strains, uptake increased when CCCP was added. Restriction fragment length analysis of the norA gene with the restriction endonuclease SfcI showed a mutation of nucleotide position 1085 in all MRSA strains tested except for one highly quinolone-resistant strain. Thus the mechanisms of 4-quinoloneresistance in these MRSA isolates involved alterations in both DNA gyrase and antimicrobial uptake and efflux.
Introduction
Met hicillin-resis tan t Staphylococcus aureus (M RSA) infections pose serious therapeutic difficulties, since only a few effective therapeutic agents are available. Although recently synthesised fluorinated 4-quinolone antibacterial agents are active against these strains, the increase in the clinical use of 4-quinolones has led to the widespread emergence of 4-quinolone-resistant strains.' Three possible mechanisms of resistance to 4-quinolones have been described : (1) alteration of DNA gyrase (gyrA), (2) existence of an efflux system (norA) and alterations in the cfx-ofx locus. Previous workers have purified DNA gyrases from 4-quinolone-resistant MRSA and reported both alterations of subunit A of the enzyme as well as the accumulation of 4-quinolones in MRSA.2*3 DNA gyrase is a tetrameric protein consisting of two A and B subunits encoded by the gyrA and gyrB genes, respectively. Several point mutations in gyrA that confer high-level fluoroquinolone resistance have been described.'-' The membrane-associated active efflux pump (norA) has also been reported as a mechanism of resistance,*-lo and the cfx-ofx locus reported by Trucksis et al." conferred low-level resistance (4-8-fold increase in MIC) to 4-quinolones.
Clinical isolates of MRSA from Japan and China were examined for 4-quinolone susceptibility along with the inhibitory action of these drugs on the supercoiling activities of DNA gyrases from the isolates and their uptake of ofloxacin. Genetic studies were also performed to identify the mechanism(s) of resistance to quinolones. *, Strain isolated in China; t , strain isolated in Japan.
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Materials and methods
Bacterial strains
Fluoroquinolone-susceptible and -resistant MRSA were from six hospitals in Japan (92 isolates) and from the Hua Shan Hospital, Shanghai, China (33 isolates) and were isolated during [1987] [1988] [1989] [1990] . A fluoroquinolone-resistant methicillin-susceptible S. aureus (MSSA) isolate from Japan and S. aureus FDA 209-P were also used as controls.
An timicrobial agents
The 4-quinolones ofloxacin, levofloxacin, DU6859a,12 DV-775 la,13 ciprofloxacin, sparfloxacin, tosufloxacin and norfloxacin as well as nalidixic acid were synthesised at Daiichi Pharmaceutical Co., Ltd. Methicillin, kanamycin, vancomycin, rifampicin and chloramphenicol were purchased from Sigma. Tetracycline and minocycline were obtained from Lederle Japan (Tokyo, Japan). Gentamicin and amikacin were obtained from Schering Plough (Osaka, Japan) and Banyu Pharmaceutical Co. (Tokyo, Japan), respectively.
MIC determination
MICs were determined by standard agar dilution methods1* with Mueller-Hinton Agar (Difco). One loopful (5 pl) of an inoculum from an overnight culture, corresponding to c. lo4 cfu/spot, was inoculated on drug-containing agar plates and the plates were incubated for 18 h at 37°C. The MIC was defined as the lowest drug concentration that prevented visible growth of bacteria.
Inhibition of DNA gyrase
DNA gyrases were purified from S. aureus FDA 209-P and quinolone-resistant strains and assayed for quinolone inhibition of DNA supercoiling activity as described previo~s1y.l~ The enzyme activity introduced into each reaction mixture was 1 unit15 and the purity of subunit A and B was almost 90% on SDS-PAGE.
Nucleotide sequence analysis of the gyrA gene
Polymerase chain reaction (PCR) amplification of part of the gyrA gene from quinolone-resistant strains was performed by the method of Hori et al." PCRamplified DNA was sequenced by the cycle sequencing method1' with a commercially available kit (New England Biolabs Co.). Thirty-five cycles were performed for each reaction as follows: 1 min at 93"C, 1 min at 94"C, 1 min at 66"C, and 1.5 min at 74°C. The partial nucleotide sequences corresponding to the nucleotide positions 120-345 of the gyrA genes of S. aureus FDA 209-P and the resistant strains were determined.
Uptake of quinolones
The uptake of ofloxacin by S. aureus cells was Restriction fragment length analysis of the norA gene PCR amplification of part of the norA gene from 4-quinolone-resistant strains was performed by the method of Kaatz et a l l 9 PCR-amplified DNA (0-5 mg/L) was digested with the restriction endonuclease SfcI and subjected to agarose gel electrophoresis. SfcI digestion of the product which has cytosine at nucleotide position 1085 results in restriction fragments of 408 and 323 bp, whereas a substitution of adenine at this position eliminates the restriction site and leaves the 731-bp PCR product intact. Table I shows the MICs of antibacterial agents against S. aureus FDA 209-P (standard strain), six MRSA (one 4-quinolone-susceptible and five -resist- 
Results
Susceptibility testing
Inhibitory effect on DNA gyrases
The inhibitory effects of 4-quinolones against the supercoiling activities of DNA gyrases are shown in table 11. The 50 O/ O inhibitory concentrations (IC50s) of levofloxacin against purified DNA gyrases from quinolone-resistant MRSA were at least 20-fold higher than those against DNA gyrases from quinolonesusceptible MRSA 87-53 and S. aureus FDA 209-P. ICSOs of sparfloxacin against S. aureus strains 89-33 and 90-37 were 2-3-fold higher than those against S. aureus strains 891185 and 900165 although the MIC values were in the reverse order. This tendency was also observed for levofloxacin. The difference in MICs against strains moderately and highly resistant to quinolones was not reflected in the inhibition of DNA gyrases. Although the MIC values of ofloxacin were the same in two quinolone-susceptible strains, the DNA gyrase from strain 87-53 had a four-fold increase in IC50 for ofloxacin than the enzyme from FDA 209-P. This might be caused by differences in the uptake of quinolones. Reconstitution assay of subunits A and B from quinolone-resistant and -susceptible S. aureus strains showed that quinolone-resistant MRSA had a mutation in subunit A of DNA gyrase (table 111) .
Nucleotide sequence analysis of the gyrA gene
The partial nucleotide sequences corresponding to the nucleotide positions 120-345 of the gyrA genes of $A ' + ' indicates that the DNA fragment has the mutation of cytosine at nucleotide position 1085, rather than adenine, and is thus susceptible to restriction digestion.
13 MRSA strains (five moderately resistant and eight highly resistant to 4-quinolones), one 4-quinolonesusceptible MRSA, one 4-quinolone-resistant MSSA and strain FDA 209-P were determined (table IV) . Eleven of these 13 strains (four moderately resistant and seven highly resistant to quinolones) contained a Ser +Leu substitution caused by an alteration at codon 84, and two strains moderately resistant and was added. The ratio of the amount of ofloxacin in MRSA moderately resistant to 4-quinolones in the presence and absence of CCCP ranged from 1.02 to 1.39; these values are less than double the ratio in S. aureus FDA 209-P. In contrast, this ratio in strains highly resistant to 4-quinolones ranged from 1.55 to 5.68.
one highly resistant to 4-quinolones contained a Glu-Lvs substitution caused by an alteration at Restriction fragment length analysis of the norA gene codon 88. Eight MRSA, including one 4-quinolonesusceptible strain and one MSSA, contained a silent mutation at codon 86.
SfcI-digestion of the PCR product with cytosine instead of adenine at nucleotide position 1085 results in restriction fragments of 408 and 323 bp. Thirteen of 14 MRSA strains showed a mutation in norA at codon 362 ; strain FDA 209-P, one 4-quinolone-resistant MSSA (strain 890405) and one 4-quinolone-resistant MRSA (strain 890958) had no mutation in norA at codon 362 (table V). The latter two strains were less resistant to ofloxacin than the other six Japanese Uptake of ofloxacin by MRSA Uptake of ofloxacin by S. aureus cells is shown in table V. The amount of ofloxacin in 4-quinolonesusceptible strains remained unchanged when CCCP strains (table I) . This result showed no correlation with the uptake of ofloxacin.
Discussion
The pattern of susceptibility of MRSA strains to antimicrobial agents varied between the two countries. Japanese strains were less resistant to antibiotics than the Shanghai strains. In Japan, the use of rifampicin is generally limited only to the treatment of tuberculosis, and the use of tetracyclines and chloramphenicol is now insignificant. Vancomycin had a good antibacterial activity against all S. aureus strains and tetracyclines and gentamicin are expected to have clinical efficacy against MRSA infections in Japan. However, the level of resistance to quinolones was lower in China than Japan, where 4-quinolones have been used for 10 years. In China, although other antibiotics have long been widely used, 4-quinolones were only introduced in 1987 although their usage has recently increased (personal communication, Dr Wang Fu, Shanghai Medical University).
In the present study, the mechanism(s) of resistance to 4-quinolones among MRSA strains were investigated. DNA gyrase was purified and the MICs of 4-quinolones for various MRSA strains were determined. Although MIC values against MRSA were different, IC50 values were similar, with the predominant mutation occurring in the A subunit of DNA gyrase. Nucleotide sequence analysis of the gyrA gene showed that 11 strains (four moderately resistant and seven highly resistant to 4-quinolones) contained a Ser + Leu substitution resulting from a mutation in codon 84, and that two strains moderately resistant and one highly resistant to 4-quinolones contained a Glu + Lys substitution resulting from a mutation in codon 88. Mutations at codons 84, 85 and 88 have been reported to confer quinolone resistance in S. a~reus;~-' however, no mutation at codon 85 was found in this study. Moreover, a silent mutation at codon 86 was found in eight MRSA, including one 4-quinolone-susceptible strain, and in one MSSA. Tokue et al. reported this mutation in one fluoroquinolone-susceptible strain isolated in the Tohoku region of Japan.2o All the Chinese, but only two of the Japanese strains contained this point mutation.
The norA gene, which is responsible for quinolone resistance related to the efflux system, has been cloned from the chromosomal DNA of S. aureus.s-10 To clarify the difference in susceptibility to quinolones, the uptake of ofloxacin into MRSA was also examined. In strains with ofloxacin MIC values of 12-5 and 25 mg/L, the ratio of the amount of uptake without CCCP compared to that with CCCP was within twofold that of S. aureus FDA 209-P, whereas in those with MICs > 50 mg/L, this ratio ranged widely. From these results, we speculate that MRSA acquire resistance to 4-quinolones by the alteration of DNA gyrase and by the development of an active efflux system. Restriction fragment length analysis of the norA gene with the restriction endonuclease SfcI showed a mutation in norA at codon 362. This result did not correspond to the uptake of ofloxacin, and showed no regional differences. Kaatz et al. reported that an increase in transcription of the norA gene was a cause of 4-quinolone-resistance. 19 
